129 related articles for article (PubMed ID: 9447396)
21. Randomized study of biennial screening with a faecal occult blood test: results after nine screening rounds.
Kronborg O; Jørgensen OD; Fenger C; Rasmussen M
Scand J Gastroenterol; 2004 Sep; 39(9):846-51. PubMed ID: 15513382
[TBL] [Abstract][Full Text] [Related]
22. Long-term effect of faecal occult blood screening on incidence and mortality from colorectal cancer.
Hamza S; Cottet V; Touillon N; Dancourt V; Bonithon-Kopp C; Lepage C; Faivre J
Dig Liver Dis; 2014 Dec; 46(12):1121-5. PubMed ID: 25241134
[TBL] [Abstract][Full Text] [Related]
23. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult.
Towler B; Irwig L; Glasziou P; Kewenter J; Weller D; Silagy C
BMJ; 1998 Aug; 317(7158):559-65. PubMed ID: 9721111
[TBL] [Abstract][Full Text] [Related]
24. Changes in prevalence of faecal occult blood positivity over time.
Goulding A; Clark GR; Anderson AS; Strachan JA; Fraser CG; Steele RJ
J Med Screen; 2019 Dec; 26(4):191-196. PubMed ID: 31364470
[No Abstract] [Full Text] [Related]
25. Hemoccult screening for colorectal cancer.
Chang FC; Jackson TM; Jackson CR
Am J Surg; 1988 Dec; 156(6):457-9. PubMed ID: 3202256
[TBL] [Abstract][Full Text] [Related]
26. Excellent performance of Hemoccult Sensa in organised colorectal cancer screening.
Kershenbaum A; Flugelman A; Lejbkowicz F; Arad H; Rennert G
Eur J Cancer; 2013 Mar; 49(4):923-30. PubMed ID: 23099005
[TBL] [Abstract][Full Text] [Related]
27. Hemoccult should no longer be used for the screening of colorectal cancer.
Bleiberg H
Ann Oncol; 2002 Jan; 13(1):44-6. PubMed ID: 11863109
[No Abstract] [Full Text] [Related]
28. Sojourn time of preclinical colorectal cancer by sex and age: estimates from the German national screening colonoscopy database.
Brenner H; Altenhofen L; Katalinic A; Lansdorp-Vogelaar I; Hoffmeister M
Am J Epidemiol; 2011 Nov; 174(10):1140-6. PubMed ID: 21984657
[TBL] [Abstract][Full Text] [Related]
29. Repeat participation in colorectal cancer screening utilizing fecal occult blood testing: a community-based project in a rural setting.
Janda M; Hughes KL; Auster JF; Leggett BA; Newman BM
J Gastroenterol Hepatol; 2010 Oct; 25(10):1661-7. PubMed ID: 20880176
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic yield in a biennial Hemoccult-II screening program compared to a once-only screening with flexible sigmoidoscopy and Hemoccult-II.
Rasmussen M; Fenger C; Kronborg O
Scand J Gastroenterol; 2003 Jan; 38(1):114-8. PubMed ID: 12608473
[TBL] [Abstract][Full Text] [Related]
31. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
[TBL] [Abstract][Full Text] [Related]
32. Screening for colorectal cancer by immunochemical fecal occult blood testing.
Saito H
Jpn J Cancer Res; 1996 Oct; 87(10):1011-24. PubMed ID: 8957057
[TBL] [Abstract][Full Text] [Related]
33. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan.
Yang KC; Liao CS; Chiu YH; Yen AM; Chen TH
J Med Screen; 2006; 13 Suppl 1():S8-13. PubMed ID: 17227635
[TBL] [Abstract][Full Text] [Related]
34. Validity of immunological faecal occult blood screening for colorectal cancer: a follow up study.
Nakama H; Kamijo N; Abdul Fattah AS; Zhang B
J Med Screen; 1996; 3(2):63-5. PubMed ID: 8849761
[TBL] [Abstract][Full Text] [Related]
35. Randomised study of screening for colorectal cancer with faecal-occult-blood test.
Kronborg O; Fenger C; Olsen J; Jørgensen OD; Søndergaard O
Lancet; 1996 Nov; 348(9040):1467-71. PubMed ID: 8942774
[TBL] [Abstract][Full Text] [Related]
36. [Test and programme sensitivities of screening for colorectal cancer in Reggio Emilia].
Campari C; Sassatelli R; Paterlini L; Camellini L; Menozzi P; Cattani A
Epidemiol Prev; 2011; 35(2):118-24. PubMed ID: 21628755
[TBL] [Abstract][Full Text] [Related]
37. Positivity rates and performances of immunochemical faecal occult blood tests at different cut-off levels within a colorectal cancer screening programme.
Faivre J; Dancourt V; Manfredi S; Denis B; Durand G; Gendre I; Bidan JM; Jard C; Levillain R; Jung S; Viguier J; Dorval E
Dig Liver Dis; 2012 Aug; 44(8):700-4. PubMed ID: 22542582
[TBL] [Abstract][Full Text] [Related]
38. Tailored telephone counselling to increase participation of underusers in a population-based colorectal cancer-screening programme with faecal occult blood test: A randomized controlled trial.
Denis B; Broc G; Sauleau EA; Gendre I; Gana K; Perrin P
Rev Epidemiol Sante Publique; 2017 Feb; 65(1):17-28. PubMed ID: 28089385
[TBL] [Abstract][Full Text] [Related]
39. Difference in performance of fecal immunochemical tests with the same hemoglobin cutoff concentration in a nationwide colorectal cancer screening program.
Chiang TH; Chuang SL; Chen SL; Chiu HM; Yen AM; Chiu SY; Fann JC; Chou CK; Lee YC; Wu MS; Chen HH
Gastroenterology; 2014 Dec; 147(6):1317-26. PubMed ID: 25200099
[TBL] [Abstract][Full Text] [Related]
40. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer.
Lindholm E; Brevinge H; Haglind E
Br J Surg; 2008 Aug; 95(8):1029-36. PubMed ID: 18563785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
